Cellectis(US:CLLS)2021-08-06 19:33Financial Data and Key Metrics Changes - Cellectis reported a cash position of $238 million as of August 6, 2021, down from $244 million at the end of 2020, primarily due to $59 million in net sales proceeds and $46 million in net equity proceeds raised [22][23] - The net loss attributable to shareholders, excluding Calyxt, was $43 million in the first half of 2021, compared to a net income of $3 million in 2020, driven by a decrease in revenues and an increase in R&D expenses [24][25] - The consolidated net loss attributable to shareholders, including Calyxt, was $52 million or $1.17 per share in the first half of 2021, compared to $12 million or $0.29 per share in 2020 [25] Business Line Data and Key Metrics Changes - Cellectis has made significant progress in its clinical trials, including enrolling patients in three Phase 1 dose-escalation trials for UCART22, BALLI-01, and UCARTCS1 [9][10] - The company presented preliminary data for UCARTCS1 at a major conference, validating CS1 as a target for CAR T-cell therapy in multiple myeloma [10] Market Data and Key Metrics Changes - Cellectis has entered into a partnership with Sanofi for the supply of alemtuzumab, which will be used in certain UCART clinical trials, indicating a strategic move to enhance clinical trial support [16] - The company is also focused on expanding its pipeline with new product candidates targeting various cancers, including solid tumors [12][13] Company Strategy and Development Direction - Cellectis aims to leverage its gene editing platform to develop novel proprietary medicines for serious diseases, focusing on hematologic malignancies and solid tumors [27] - The company plans to file INDs for new product candidates in 2022, including UCART20x22 and UCART mesothelin [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering a new phase of development, emphasizing clinical execution and internal product manufacturing capabilities [8][27] - The company is focused on developing its pipeline while maintaining efficient cash management to support operations into early 2023 [22][26] Other Important Information - Cellectis has successfully completed two UCART training runs in its Raleigh GMP manufacturing facility, marking a key milestone in its manufacturing capabilities [18] - The company is preparing to organize a live visit of its manufacturing facility for investors, showcasing its state-of-the-art capabilities [83] Q&A Session Summary Question: Will data for UCART22 be presented at ASH? - Management aims to present data at ASH, with some cohorts expected by the end of the year [31] Question: Thoughts on moving HEAL technology to in-vivo systems? - The focus is currently on ex-vivo systems, with plans to transition to in-vivo once safety and efficacy are established [34] Question: Long-term partnering strategy? - Cellectis remains open to partnerships to accelerate clinical execution, considering past collaborations as beneficial [39][40] Question: Update on UCARTCS1 trial progress? - The trial is progressing well, but specific enrollment numbers are not disclosed due to safety monitoring requirements [70] Question: IP perspective on UCART MK1? - Cellectis believes it has a strong IP position in gene editing, having filed patents long before competitors [60] Question: Solid tumor strategy and first targets? - The first target for solid tumors is likely to be mesothelin CAR-T, focusing on indications like mesothelioma and pancreatic cancer [65]